"女律师体检10年未提示癌症"的体检门事件持续发酵。7月30日，身陷信任危机的爱康国宾官宣强势回 击动作。 在7月30日举行的媒体说明会上，爱康集团就"10年体检未预警肾癌"事件进行回应和澄清。会上爱康集 团高管郑重宣布：已就张女士虚构事实、散布谣言的侵权行为向法院提起正式诉讼，并获法院受理并立 案。 "张女士本应秉持职业操守，她却罔顾事实，通过造谣污蔑手段，通过网络媒体大肆发酵爱康国宾假体 检言论，开展了一场对爱康有组织的网暴。由于其行为严重损害爱康声誉，让每年约800万体检客户蒙 羞，更让民众对私营体检中心，乃至中国整个医疗行业产生不信任。在上述情况下，爱康认为，必须要 澄清事实，还原真相，爱康代表1.5万名爱康员工，向人民法院提请诉讼，现已正式立案受理。"公司高 管在会上表示。 对于爱康国宾今日的发布会，当事人张晓玲律师则告诉媒体，她已关注到，并录屏。 张晓玲表示，"我非常期待他们起诉我。目前还没看到对方发来的起诉状，没有接到任何通知。但已做 好100%的准备，随时应诉。" "体检不等于看病诊断" 发布会现场，爱康集团创始人、董事长兼CEO张黎刚提供了一组数字——中国每一年确诊的癌症患者大 约有480万 ...

Core Viewpoint - The company Aikang Guobin is facing public scrutiny and legal action following allegations from a client, Ms. Zhang, who claims that her cancer was not detected during ten years of health check-ups, leading to a lawsuit against her for defamation [2][6]. Group 1: Company Response - Aikang Guobin held a media briefing to address the allegations, stating that Ms. Zhang's health check on October 9, 2023, indicated a "possible renal hamartoma," which suggests a potential cancer diagnosis [2][3]. - The company emphasized that Ms. Zhang's health checks were part of a basic package provided by the Beijing Bar Association, and she had not purchased any additional services except in 2017 [3]. - Aikang Guobin's CEO, Zhang Ligang, commented on public misconceptions regarding the effectiveness of low-cost health checks, questioning the expectation that a basic check costing a few hundred yuan could detect all diseases [11]. Group 2: Public Reaction and Concerns - Public skepticism arose regarding the value of health checks if they fail to detect serious conditions, with many questioning the purpose of offering such services [3][11]. - Ms. Zhang publicly demanded transparency from Aikang Guobin, requesting the release of her past ultrasound results and the qualifications of the personnel involved in her checks [6][11]. - Complaints against Aikang Guobin have surged, with over a thousand reports on platforms like Black Cat Complaints, citing issues such as inaccurate results and misleading practices [14]. Group 3: Industry Context - The incident has highlighted broader concerns within the health check industry, with previous allegations of malpractice and the existence of "fake health checks" being raised by industry insiders [14]. - The CEO's past revelations about the industry's integrity have come back to haunt him, as the company now faces a "crisis of trust" among the public [14].

超声与癌胚抗原争议 爱康集团体检超声专业组组长黄英对2023年10月张女士在爱康集团进行的超声报告进行了解读。她指出，张女士对外声称的2023年的超声检查描述"右肾钙 化灶、有低回声"属于编造，与其实际的超声报告不符。只要张女士提供书面授权，爱康集团可以直接对外公布张女士的超声检查的具体描述。 关于张女士所述"癌胚抗原（CEA）"检测正常一事，爱康集团副总裁汪朝晖进行回应，表示肾癌早期诊断主要依赖影像学（CT/MRI）而非血液检测（美国 NCCN指南2024）。癌胚抗原（CEA）主要用于结直肠癌、胃癌等消化道肿瘤辅助诊断和病情监测。2022版《肾细胞癌诊疗指南》明确指出，"目前尚无公 认的用于肾细胞癌早期辅助诊断的血清肿瘤标志物"，即CEA与肾细胞癌筛查无医学关联性，不能用于是否存在肾细胞癌的风险评估。 对张女士提出的"假体检"指控，汪朝晖在说明会上进行了否认。他现场展示了张女士历次体检中癌胚抗原（CEA）检测的脱敏质量控制图，并强调"所有质 控数据均可在爱康存储系统中完全追溯，随时可提交政府主管部门核查"，不存在任何"假体检"的可能。 张女士十年检测数据已上交 7月30日，爱康集团在京召开媒体说明会，就近期 ...

凤凰网财经讯 7月30日上午，爱康集团举行媒体说明会，针对此前与张女士的癌症检查纠纷，爱康集团 资深副总裁周晓江宣布，已向法院提起诉讼，法院已正式立案受理。爱康集团董事长张黎刚表示，为了 维护爱康15000名员工的尊严，为了给行业正名，爱康不得不做出这个非常艰难的决定。 随后，爱康体检事件当事人@张晓玲律师再发微博喊话爱康国宾:"别遮遮掩掩的了，把我的10年超声检 查公布出来、给我检查的人员名单和资质公布出来、第三方是谁公布出来、结果公布出来，起诉内容公 布出来，我没也别整假患者、伪专家了!"她还表示，自己也没有收到爱康起诉的内容。 在上午举行的发布会上，爱康集团创始人、董事长兼CEO张黎刚表示，体检不等于看病诊断，其服务模 式不同于专科医生接诊，可以说是由体检套餐决定的，最主要的功能是帮助受检者发现疾病的蛛丝马 迹，后续找专科医生做进一步的诊断，而非替代临床诊断。因此，无论是在独立的体检中心还是在三甲 医院的体检中心，服务模式都是一样的。预防是最为经济有效的健康管理策略。健康体检作为预防医疗 的核心手段之一，一直以来都在发挥着积极的作用。 ...

7月30日，据东方财经等多家媒体消息，在上午的说明会上，爱康国宾表示，张女士造谣令员工深受伤害，已向法院提起诉讼，法院已正式立案受理。爱 康集团董事长张黎刚表示，为了维护爱康员工的尊严，为了给行业正名，爱康不得不做出这个非常艰难的决定。 会上，爱康国宾公开回应张女士体检报告，并表示根据现有公开信息，北大医院病例报告明确标注是早期肾癌，而不是张女士所述的晚期。 爱康国宾相关负责人李秀池在说明会称，张女士在爱康国宾的十年体检均为北京律师协会提供的福利基础套餐。除2017年外，张女士没有自费购买任何特 色或升级项目。 李秀池表示，张女士2023年10月9日在北京爱康国宾西内门诊部参加健康体检，体检结果显示有肾错构瘤可能。爱康国宾建议"首次发现者需要做CT，以 除外其他肾脏占位性病变"，李秀池称，"除外其他肾脏占位性病变"即是提示癌症可能性。 爱康国宾还公布了张女士2023年10月9日在北京爱康国宾西内门诊部参加体检的部分报告，其中专家建议与指导部分显示：肾钙化灶和肾错构瘤可能。 会上，爱康国宾还回应了"体检到底有没有用"这一问题。爱康国宾方表示：体检的核心是发现风险信号，而不是做出最终诊断。体检的意义是通过检查项 ...

每经编辑｜陈柯名 7月30日，据东方财经等多家媒体消息，在上午的说明会上，爱康国宾表示，张女士造谣令员工深受伤害，已向法院提起诉讼，法院已正式立案受理。爱 康集团董事长张黎刚表示，为了维护爱康员工的尊严，为了给行业正名，爱康不得不做出这个非常艰难的决定。 爱康国宾相关负责人表示，当事人张女士罔顾事实，通过网络臆想造谣、污蔑爱康国宾"假体检"，并恶意发酵。此举严重损害爱康国宾声誉，深深伤害了 二十余年来专注健康服务的数万名员工，更误导公众，引发对私营体检中心、乃至整个中国医疗行业的不当质疑。为澄清事实，还原真相，爱康国宾已依 法向法院提起诉讼，目前案件已获正式立案。 图片来源：红星新闻 会上，爱康国宾公开回应张女士体检报告，并表示根据现有公开信息，北大医院病例报告明确标注是早期肾癌，而不是张女士所述的晚期。 爱康国宾相关负责人李秀池在说明会称，张女士在爱康国宾的十年体检均为北京律师协会提供的福利基础套餐。除2017年外，张女士没有自费购买任何特 色或升级项目。 李秀池表示，张女士2023年10月9日在北京爱康国宾西内门诊部参加健康体检，体检结果显示有肾错构瘤可能。爱康国宾建议"首次发现者需要做CT，以 除外其他 ...

Core Viewpoint - The controversy surrounding Aikang Guobin involves allegations of "fake health check-ups" after a lawyer, Zhang Xiaoling, was diagnosed with cancer despite years of normal test results from the company [1][2]. Group 1: Allegations and Responses - Zhang Xiaoling claims that Aikang Guobin's health checks failed to detect her cancer risk over a decade, leading to a late-stage diagnosis [1][2]. - Aikang Guobin has conducted internal and external evaluations, asserting that there were no misdiagnoses or false checks, and has initiated legal action against Zhang for defamation [2][6]. - The company emphasizes that health checks are not equivalent to medical diagnoses and are intended to identify potential health issues for further investigation by specialists [3]. Group 2: Medical Insights and Procedures - Aikang Guobin's medical professionals clarified that the 2023 ultrasound report indicated potential issues that warranted further examination, contradicting Zhang's claims [3][5]. - The company highlighted that cancer markers like carcinoembryonic antigen (CEA) are not reliable for early detection of kidney cancer, as imaging techniques are the primary diagnostic tools [5]. - Aikang Guobin maintains that it follows industry standards regarding the retention of blood samples, which typically last only 1-7 days, making it impossible to keep samples from the past decade [4]. Group 3: Impact on the Industry - The allegations have raised concerns about public trust in private health check-up centers and the broader healthcare industry in China, affecting the reputation of Aikang Guobin and its employees [6]. - The company asserts that the claims have harmed its reputation and the trust of its approximately 8 million annual clients [6].

Core Viewpoint - Aikang Guobin has initiated legal proceedings regarding a dispute over cancer screening with a client, Ms. Zhang, and the court has officially accepted the case [1] Group 1: Company Actions - Aikang Group's Senior Vice President, Zhou Xiaojiang, announced the lawsuit against Ms. Zhang during a press conference [1] - The company emphasizes the importance of seeking specialized medical advice if abnormalities are detected during health check-ups [1] Group 2: Industry Insights - Aikang Group's founder and CEO, Zhang Ligang, stated that cancer development is a gradual process and early detection may be limited by technological constraints [1] - The company highlights that health check-ups cannot replace specialized medical diagnosis and further examinations are necessary if any issues are found [1]

Core Viewpoint - The case of Zhang Xiaoling highlights significant concerns regarding the reliability of commercial health check-up services, particularly in cancer detection, raising questions about the effectiveness of routine screenings and the potential for misdiagnosis [2][4][27]. Group 1: Company and Service Reliability - Zhang Xiaoling underwent annual health check-ups at Aikang Guobin for ten years without being informed of any cancer risks, despite her eventual diagnosis of advanced kidney cancer [2][8]. - Aikang Guobin stated that they had reviewed Zhang's medical records and found no flaws in their kidney examinations, asserting their lack of responsibility in her case [3][7]. - The incident has sparked public debate about the trustworthiness of commercial health check-up institutions and the adequacy of cancer screening methods [4][27]. Group 2: Screening Limitations - Experts suggest that routine health check-ups primarily identify chronic diseases like hypertension and diabetes, with limited effectiveness in cancer detection [5][29]. - Various screening methods, such as ultrasound and CT scans, have inherent limitations, and a combination of different tests is recommended for more accurate results [5][19]. - The common use of tumor markers like CEA in screenings is criticized, as they are not reliable for early detection of certain cancers, including kidney cancer [11][12][14]. Group 3: Patient Experience and Misdiagnosis - Zhang's experience reflects a broader issue where patients report instances of missed cancer diagnoses despite normal results from commercial health check-ups [6][27]. - Misinterpretation of test results and inadequate communication from health check-up providers can lead to delayed diagnoses and treatment [16][18]. - The case emphasizes the need for better patient education regarding the significance of test results and the importance of follow-up examinations when abnormalities are detected [8][19]. Group 4: Recommendations for Improvement - Medical professionals recommend that individuals, especially those at higher risk, should seek more comprehensive evaluations, including advanced imaging techniques like CT or MRI, rather than relying solely on routine check-ups [30][31]. - Regular health screenings should be tailored to individual health profiles, considering factors such as age, family history, and existing health conditions [30][36]. - The importance of maintaining personal health records and undergoing early cancer screenings is emphasized to improve early detection rates and treatment outcomes [35][36].

Meeting Overview - The shareholders' meeting of Meinian Health Industry Holdings Co., Ltd. was held on July 28, 2025, with a total of 921 participants representing 1,277,900,984 shares, accounting for 32.6474% of the total shares [1] - The online voting took place from 9:15 AM to 3:00 PM on the same day, with 916 shareholders participating, representing 749,647,534 shares, or 19.1517% of the total shares [2] Voting Results - The meeting adopted resolutions with a significant majority, where 1,272,894,440 shares voted in favor, representing 99.6082% of the valid votes [2] - A total of 4,509,144 shares opposed the resolutions, accounting for 0.3529%, while 497,400 shares were abstained [2] Minority Shareholder Participation - Among the minority investors, 282,237,144 shares voted in favor, which is 98.2570% of the valid votes from minority shareholders [3] - The opposition from minority shareholders was 4,509,144 shares, representing 1.5698% [3] Related Party Transactions - The resolutions involved related party transactions, with specific shareholders, including Yu Rong and several asset management companies, abstaining from voting [3][4] - The voting results from non-related shareholders showed 738,065,801 shares in favor, which is 98.4550% of the valid votes [4] Detailed Voting Breakdown - The detailed voting results indicated that among non-related minority shareholders, 275,661,955 shares voted in favor, representing 95.9680% [4] - The opposition from this group was 11,086,633 shares, accounting for 3.8597% [4] Conclusion of Resolutions - All resolutions requiring a two-thirds majority from non-related shareholders were successfully passed according to the company's articles of association [4][5] - The resolutions included significant related party transactions, with the relevant shareholders abstaining from the voting process [5][6]